SAC Capital Advisors’s Bristol-Myers Squibb BMY Stock Holding History

SAC Capital Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,821,145	Closed	-$94.6M	–	153
2014 Q1	$94.6M	Buy	1,821,145 +1,190,546	+189%	+$63.4M	0.49%	34
2013 Q4	$33.5M	Sell	630,599 -1,211,383	-66%	-$61.7M	0.19%	132
2013 Q3	$85.2M	Buy	1,841,982 +1,346,960	+272%	+$59.1M	0.46%	42
2013 Q2	$22.1M	Buy	+495,022	New	+$21.5M	0.12%	225

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SAC Capital Advisors's BMY Position: Q2 2014 in Review

SAC Capital Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2014, closing a stake of 1,821,145 shares — an estimated $94.6M sold.

SAC Capital Advisors first reported a position in BMY in Q2 2013 and held it in 4 quarters. The position peaked at $94.6M in Q1 2014. 1,301 funds tracked by Wall St. Rank hold BMY as of Q2 2014.

SAC Capital Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2014 after selling out during the quarter.
SAC Capital Advisors sold 1,821,145 Bristol-Myers Squibb shares in Q2 2014, an estimated $94.6M.
SAC Capital Advisors first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 4 quarters.
SAC Capital Advisors's Bristol-Myers Squibb position peaked at $94.6M in Q1 2014.
1,301 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.